{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:45:13Z","timestamp":1792277113869,"version":"4.4.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ropeginterferon alfa-2b, a novel monopegylated interferon with improved pharmacokinetics, has emerged as a promising cytoreductive agent for managing polycythemia vera (PV). Despite increasing adoption, evidence synthesis of its efficacy and safety compared to standard care remains limited. The manuscript aimed to evaluate the efficacy of ropeginterferon alfa-2b in comparison to standard treatment options, including hydroxyurea and phlebotomy, in achieving complete hematologic response, partial molecular response (PMR), and reducing JAK2V617F allele burden in patients with PV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic search of 4 databases was conducted up to April 2025, following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing ropeginterferon alfa-2b with standard therapies in PV patients were included. Meta-analyses were performed using random-effects models to derive odds ratios for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Sensitivity and subgroup analyses were conducted, and risk of bias was assessed using RoB 2.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Three RCTs comprising 522 patients were analyzed. Ropeginterferon alfa-2b showed no statistically significant advantage overall or over hydroxyurea for complete hematological response (CHR), PMR, or JAK2 allele burden reduction. However, subgroup analyses revealed significant benefits over phlebotomy alone in all 3 outcomes: CHR (odds ratio [OR] 3.05; 95% confidence interval [CI]: 1.36\u20136.80;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.007), PMR (OR 36.34; 95% CI: 2.11\u2013625.93;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.01), and allele burden reduction (MD \u221213.70; 95% CI: \u221219.24 to \u22128.16;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.00001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ropeginterferon alfa-2b demonstrates no statistically significant difference compared to hydroxyurea, but gives better outcomes over phlebotomy in short-term efficacy for PV management. Its favorable molecular and hematologic outcomes support its role as a disease-modifying therapy, particularly in low-risk patients. However, larger and longer-term trials are needed to confirm these benefits across broader populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050143","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:01:57Z","timestamp":1786125717000},"page":"e50143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Danyal","family":"Bakht","sequence":"first","affiliation":[{"name":"King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Haris","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sania","sequence":"additional","affiliation":[{"name":"Women Medical and Dental College, Khyber Medical University, Abbottabad, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian Maroof Shah","family":"Bahadri","sequence":"additional","affiliation":[{"name":"Gomal Medical College, Khyber Medical University, Abbottabad, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allah","family":"Dad","sequence":"additional","affiliation":[{"name":"Shiekh Zayed Medical College, Rahim Yar Khan, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alizah Rehman","family":"Mirza","sequence":"additional","affiliation":[{"name":"Al Aleem Medical College, Gulab Devi Teaching Hospital Lahore, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Nayyar","sequence":"additional","affiliation":[{"name":"Women Medical and Dental College, Khyber Medical University, Abbottabad, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryum","family":"Amyn","sequence":"additional","affiliation":[{"name":"Bakhtawar Amin Medical and Dental College, Bakhtawar Amin Memorial Trust Hospital, Multan, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Zahid","sequence":"additional","affiliation":[{"name":"Women Medical and Dental College, Khyber Medical University, Abbottabad, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9644-2272","authenticated-orcid":false,"given":"Muhammad Numan","family":"Awais","sequence":"additional","affiliation":[{"name":"Shaheed Ziaur Rahman Medical College, Shaheed Ziaur Rahman Medical Hospital, Bogura, Rajshahi, Bangladesh."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minahil","family":"Faheem","sequence":"additional","affiliation":[{"name":"Bakhtawar Amin Medical and Dental College, Bakhtawar Amin Memorial Trust Hospital, Multan, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minahil","family":"Waheed","sequence":"additional","affiliation":[{"name":"Al Aleem Medical College, Gulab Devi Teaching Hospital Lahore, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alssa Omer","family":"Alvi","sequence":"additional","affiliation":[{"name":"Al Aleem Medical College, Gulab Devi Teaching Hospital Lahore, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/s41375-021-01401-3","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.","volume":"35","author":"Tefferi","year":"2021","journal-title":"Leukemia"},{"key":"R2-20260807","first-page":"680","article-title":"Polycythemia vera: rapid evidence review.","volume":"103","author":"Fox","year":"2021","journal-title":"Am Fam Physician"},{"key":"R3-20260807","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.3390\/ijms21165805","article-title":"New perspectives on polycythemia vera: from diagnosis to therapy.","volume":"21","author":"Iurlo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera.","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.","volume":"97","author":"van Genderen","year":"1997","journal-title":"Br J Haematol"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-020-00564-7","article-title":"Novel therapies in polycythemia vera.","volume":"15","author":"Tremblay","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.","volume":"15","author":"Mesa","year":"2017","journal-title":"J Nat Compr Cancer Netw"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera.","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera.","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for Polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera.","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R21-20260807","first-page":"848","article-title":"New guidelines from the NCCN for polycythemia vera.","volume":"15","author":"Mesa","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41375-025-02623-5","article-title":"Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).","volume":"39","author":"Heidel","year":"2025","journal-title":"Leukemia"},{"key":"R23-20260807","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.clinthera.2024.03.005","article-title":"Mechanism of action of ropeginterferon Alfa-2b in polycythemia vera treatment.","volume":"46","author":"Qin","year":"2024","journal-title":"Clin Ther"},{"key":"R24-20260807","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera \u2013 a systematic review and meta-analysis.","volume":"35","author":"Bewersdorf","year":"2021","journal-title":"Leukemia"},{"key":"R25-20260807","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/jh1245","article-title":"Effective management of polycythemia vera with ropeginterferon Alfa-2b treatment.","volume":"13","author":"Suo","year":"2024","journal-title":"J Hematol"},{"key":"R26-20260807","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1080\/10428194.2024.2361836","article-title":"Polycythemia vera: past, present and future.","volume":"65","author":"Patel","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"R27-20260807","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review.","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"key":"R28-20260807","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000544818","article-title":"ECLIPSE-PV: a randomized, multicenter study to assess efficacy, safety, and tolerability of two dosing regimens of ropeginterferon Alfa-2b-Njft in polycythemia vera.","volume":"148","author":"Mascarenhas","year":"2025","journal-title":"Acta Haematol"},{"key":"R29-20260807","first-page":"335","article-title":"PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.","volume":"104","author":"Yacoub","year":"2025","journal-title":"Ann Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:02:35Z","timestamp":1786132955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":28,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050143","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"2025-08-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}